- Keryx Biopharmaceuticals (KERX +3.6%) perks up average volume in response to its announcement of more detailed results from its Phase 3 clinical trial assessing Auryxia (ferric citrate) for the treatment of iron deficiency in adults with stage 3-5 non-dialysis-dependent chronic kidney disease (CKD). The data are being presented at the American Society of Nephrology's 2016 Kidney Week in Chicago.
- As was previously announced in March, the study met its primary and secondary endpoints. 52% (n=61/117) of participants achieved at least a 1 g/dL increase in hemoglobin at some point in the 16-week efficacy period and 93.4% (n=57/61) of these patients experienced a sustained treatment effect.
- Auryxia was approved in the U.S. in September 2014 for the control of serum phosphorus levels in CKD patients on dialysis.
- Previously: Keryx Bio's Auryxia successful in label-expanding late-stage study; shares up 21% premarket (March 29)
Original article